Find Clinical Trials & Studies

Visit the Research & Education Institute

Lupus Nephritis Phase 2 study of rapcabtagene autoleucel in SLE patients with active, refractory LN

I'm Interested!

A Phase 2, adaptive, randomized, open-label, assessor blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)

Sex: Any
Age: Adult (18 - 64)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase II
Conditions Being Studied: Systemic Lupus Erythematosus

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel following the selected lymphodepletion regimen versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).

Who Can Participate

Age: 18 - 65 years old

Principal Investigator
Ansaam Daoud MD

Department/Division
Medicine (Rheumatology)

UH IRB: SITE00002500
StudyID: 2025-01713
ClinicalTrials.gov: N/A

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464